{
    "clinical_study": {
        "@rank": "163080", 
        "arm_group": {
            "arm_group_label": "Angel\u00ae Catheter", 
            "arm_group_type": "Experimental", 
            "description": "All eligible subjects will receive an Angel\u00ae Catheter."
        }, 
        "brief_summary": {
            "textblock": "The primary objective of this clinical trial is to obtain initial insights into the safety\n      of the Angel\u00ae Catheter in critically ill subjects with high risk of venous thromboembolism\n      (VTE) disease AND who are not receiving pharmacological thromboprophylaxis."
        }, 
        "brief_title": "Angel\u00ae Catheter Early Feasibility Clinical Study", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pulmonary Embolism", 
            "Deep Vein Thrombosis", 
            "Venous Thromboembolism"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Critical Illness", 
                "Embolism", 
                "Pulmonary Embolism", 
                "Thromboembolism", 
                "Thrombosis", 
                "Venous Thrombosis", 
                "Venous Thromboembolism"
            ]
        }, 
        "detailed_description": {
            "textblock": "STUDY ENDPOINTS\n\n        1. Primary Endpoints:\n\n           a. Initial Insights into Safety\n\n             -  Success in delivery, maintenance and removal of the Angel\u00ae Catheter.\n\n             -  Incidence and seriousness of all adverse events.\n\n             -  Incidence of device or procedure-related adverse events.\n\n        2. Secondary Endpoints:\n\n             -  Evaluation of the separate and combined functions of the IVC filter and the\n                central venous catheter device.\n\n             -  Evaluate investigative site's ability to comprehend the procedural steps (Per the\n                Insertion Procedure, the Repositioning Procedure, and the Removal Procedure)\n\n             -  Evaluate operator challenges with device use (human factors).\n\n             -  Evaluate success and challenges encountered in conducting a pivotal trial in\n                critically ill patient population - including but not limited to Informed Consent\n                and enrollment.\n\n      ENROLLMENT AND SUBJECT SAMPLE SIZE\n\n      The study is expected to enroll up to 20 subjects in up to 4 US investigational sites with a\n      goal for 10 evaluable subjects in whom Angel\u00ae Catheter placement has been attempted.\n\n      STUDY DURATION\n\n      The device is designed to be deployed for less than 30 days. After enrollment and Angel\u00ae\n      Catheter placement, subjects will be followed daily through the post-removal, seven (7) day\n      follow up or until hospital discharge, whichever occurs first."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION CRITERIA (Must Answer YES to all Inclusion Criteria):\n\n          1. Subject or legally authorized representative is willing and able to provide written\n             informed consent, AND\n\n          2. Subject is 18 years or older, AND\n\n          3. Subject is currently admitted OR to be admitted to the Intensive Care Unit (ICU)\n             within \u226436 hours of screening, AND\n\n          4. Subject has a clinical need for a Central Venous Catheter, and/or the subject has an\n             existing Central Venous Catheter that has been in place  for <36 hours before Angel\u00ae\n             Catheter placement, AND\n\n          5. Subject is considered at high risk for PE and meets ONE of the following criteria:\n\n               1. Subject has multiple trauma with at least ONE of the following:\n\n                    -  Severe head injury\n\n                    -  Head injury with a long bone fracture\n\n                    -  Spinal cord injury with paraplegia or quadriplegia\n\n                    -  Multiple (\u22652) long bone fractures\n\n                    -  Multiple (\u22652) long bone fractures with pelvic fracture\n\n                    -  Pelvic fracture requiring open fixation\n\n               2. Critically ill subject in the Intensive Care Unit with at least ONE of the\n                  following:\n\n                    -  Hemorrhagic or ischemic stroke\n\n                    -  Multiple organ failure\n\n                    -  Active or recent bleeding (within the past 2 weeks)\n\n                    -  Severe sepsis\n\n                    -  Lower extremity DVT\n\n                    -  Anticipated ventilator requirement of greater than one week\n\n               3. Critically ill subject requiring temporary (\u226548 hours) interruption of medical\n                  thromboprophylaxis (prophylactic anticoagulation)\n\n        EXCLUSION CRITERIA (Must Answer NO to All Exclusion Criteria):\n\n          1. Subject is pregnant or lactating\n\n          2. BMI = (Weight (lb)  x 703)/(\u3016Height\u3017^2  (inches)) > 45; BMI may also be calculated at\n             http://nhlbisupport.com/bmi/bminojs.htm\n\n          3. Subject has a pre-existing IVC filter in place\n\n          4. Subject is currently receiving prophylactic anticoagulation, other than aspirin or\n             Plavix. Specifically, the subject is receiving any of the following medications:\n             heparin, low molecular weight heparin, factor Xa inhibitors (i.e. xabans), Coumadin,\n             and thrombin inhibitors.\n\n          5. Subject has a diagnosis of pulmonary embolism\n\n          6. Subject is participating in another clinical investigation\n\n          7. Subject has known hypersensitivity to any of the components of the Angel\u00ae Catheter,\n             specifically Nitinol (nickel and/or titanium)\n\n          8. Subject has functioning pelvic renal allograft on the only side available for device\n             insertion\n\n          9. Subject has  undergone a surgical procedure involving the femoral vein or pelvic\n             veins through which the device must be inserted\n\n         10. Anatomic inability to place the Angel\u00ae Catheter (including a history of thrombosis of\n             venous system on side of proposed access)\n\n         11. Anticipated survival \u226448 hours"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01847196", 
            "org_study_id": "QD-155"
        }, 
        "intervention": {
            "arm_group_label": "Angel\u00ae Catheter", 
            "description": "The Angel\u00ae Catheter combines the functions of an inferior vena cava (IVC) filter and a multi-lumen central venous catheter (CVC).  The device is designed to be placed in the inferior vena cava, via the femoral vein, for the prevention of Pulmonary Embolism (PE), and for access to the central venous system.   The device is intended for short-term use (less than 30 days) and must be removed before hospital discharge.", 
            "intervention_name": "Angel\u00ae Catheter", 
            "intervention_type": "Device", 
            "other_name": [
                "Angel Catheter", 
                "2011-0420"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pulmonary Embolism", 
            "PE", 
            "DVT", 
            "Deep Vein Thrombosis", 
            "VTE", 
            "Venous Thromboembolism", 
            "prophylaxis", 
            "thromboprophylaxis", 
            "contraindications to thromboprophylaxis", 
            "prophylactic", 
            "prevention", 
            "Inferior vena cava filter", 
            "IVC filter", 
            "filter", 
            "prevention of pulmonary embolism", 
            "trauma", 
            "critically-ill"
        ], 
        "lastchanged_date": "March 20, 2014", 
        "location": [
            {
                "contact": {
                    "email": "MDMartin@umc.edu", 
                    "last_name": "Magdeline Martin, RN", 
                    "phone": "601-815-2876"
                }, 
                "facility": {
                    "address": {
                        "city": "Jackson", 
                        "country": "United States", 
                        "state": "Mississippi", 
                        "zip": "39216"
                    }, 
                    "name": "University of Mississippi Medical Center"
                }, 
                "investigator": {
                    "last_name": "Larry Martin, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lamortik@ohsu.edu", 
                    "last_name": "Kim La Morticella, RN, BSN", 
                    "phone": "503-418-2107"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "Oregon Health and Science University"
                }, 
                "investigator": [
                    {
                        "last_name": "Martin A. Schreiber, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Laszlo Kiraly, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jeanette.M.Podbielski@uth.tmc.edu", 
                    "last_name": "Jeanette Podbielski", 
                    "phone": "713-500-6407"
                }, 
                "contact_backup": {
                    "email": "laura.e.vincent@uth.tmc.edu", 
                    "last_name": "Laura Vincent", 
                    "phone": "713 500 5216"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "University of Texas Houston"
                }, 
                "investigator": {
                    "last_name": "John Holcomb, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-center, Early Feasibility Study of the Angel\u00ae Catheter in Critically Ill Subjects at High Risk of Pulmonary Embolism", 
        "overall_official": [
            {
                "affiliation": "Oregon Health and Science University", 
                "last_name": "Martin Schreiber, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Mississippi Medical Center", 
                "last_name": "Larry Martin, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "The University of Texas Health Science Center, Houston", 
                "last_name": "John Holcomb, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "All Adverse Events (AEs) occurring throughout the study will be identified and characterized by seriousness, relationship to the investigational device and/or procedure, and whether un/anticipated.", 
            "measure": "Number of Adverse Events occuring for all evaluable subjects", 
            "safety_issue": "Yes", 
            "time_frame": "From the time of subject enrollment through study exit (7 days post-removal or hospital discharge, whichever occurs first)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01847196"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "BiO2 Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BiO2 Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}